Fatal and Nonfatal Overdose Among Pregnant and Postpartum Women in Massachusetts

Women receiving pharmacotherapy with methadone or buprenorphine had statistically significantly lower opioid overdose rates compared to women not receiving pharmacotherapy at 4-6 months postpartum (1.

Effect: improvement; 1.3 per 100,000 person-days on pharmacotherapy vs 10.7 per 100,000 person-days not on pharmacotherapy at 4-6 months postpartum; CI: 95% C

Opioid overdose rates were lowest in the third trimester (3.3 per 100,000 person-days) then increased sharply in the postpartum period, with the highest rate at 7-12 months after delivery (12.3 per 10

Effect: decline; 3.3 per 100,000 person-days (3rd trimester) rising to 12.3 per 100,000 person-days (7-12 months postpartum); CI: 95% CI 1.6-6.1 (3rd trimeste

At 7-12 months postpartum, opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment, suggesting the protective effect of pharmacotherapy waned in the

Effect: null; 12.3 per 100,000 person-days (overall rate at 7-12 months postpartum); CI: 95% CI 9.9-15.0

Among pregnant women with OUD, those who experienced an overdose had significantly higher rates of homelessness (79% vs 34%), anxiety (82% vs 60%), and depression (85% vs 61%) compared to women with O

Effect: decline; 79% homelessness with overdose vs 34% OUD without overdose vs 2% no OUD; 82% anxiety with overdose vs 60% OUD without overdose vs 18% no OUD;

Using linked administrative databases, 2.3% of deliveries in Massachusetts in 2012-2014 were to women with evidence of OUD in the year prior to delivery, higher than previously published national esti

Effect: decline; 2.3% of deliveries (4,154 of 177,876) had evidence of OUD in the year prior to delivery